{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:42:26Z","timestamp":1783453346846,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11523-025-01170-4","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:13:42Z","timestamp":1755623622000},"page":"821-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach"],"prefix":"10.1007","volume":"20","author":[{"given":"Mohamed","family":"Elmeliegy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooneh","family":"Soltantabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hibma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Ashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2526-1387","authenticated-orcid":false,"given":"Hoi-Kei","family":"Lon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"4","key":"1170_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319.","journal-title":"Nat Rev Drug Discov"},{"key":"1170_CR2","unstructured":"Blinatumomab (BLINCYTO) Mutli-Discipline Review. 2014. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125557Orig1s000PharmR.pdf. Accessed 19 Mar 2025."},{"issue":"3","key":"1170_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpt.3361","volume":"116","author":"M Elmeliegy","year":"2024","unstructured":"Elmeliegy M, et al. Dosing strategies and quantitative clinical pharmacology for bispecific T-cell engagers development in oncology. Clin Pharmacol Ther. 2024;116(3):637\u201346.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1170_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11523-025-01134-8","volume":"20","author":"M Elmeliegy","year":"2025","unstructured":"Elmeliegy M, et al. Dose optimization of elranatamab to mitigate the risk of cytokine release syndrome in patients with multiple myeloma. Target Oncol. 2025;20(2):349\u201359.","journal-title":"Target Oncol"},{"issue":"2","key":"1170_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpt.3308","volume":"116","author":"K Lim","year":"2024","unstructured":"Lim K, et al. Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin Pharmacol Ther. 2024;116(2):315\u201327.","journal-title":"Clin Pharmacol Ther"},{"key":"1170_CR6","unstructured":"Elranatamab-bcmm (ELREXFIO) [Package insert]. 2023. Pfizer; New York, NY. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19669. Accessed 19 Mar 2025."},{"key":"1170_CR7","unstructured":"Elranatamab-bcmm (ELREXFIO) [Summary of product characteristics]. 2023. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf. Accessed 19 Mar 2025."},{"key":"1170_CR8","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05020236?term=MagnetisMM-5&rank=1. Accessed 19 Mar 2025."},{"key":"1170_CR9","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05317416?term=MagnetisMM-7&rank=1. Accessed 19 Mar 2025."},{"key":"1170_CR10","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05623020?term=MagnetisMM-6&rank=1. Accessed 19 Mar 2025."},{"issue":"1","key":"1170_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clon.2006.10.010","volume":"19","author":"SA Kaestner","year":"2007","unstructured":"Kaestner SA, Sewell GJ. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol). 2007;19(1):23\u201337.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"1170_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1010639201787","volume":"19","author":"M Sawyer","year":"2001","unstructured":"Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Investig New Drugs. 2001;19(2):171\u20137.","journal-title":"Investig New Drugs"},{"issue":"10","key":"1170_CR13","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","volume":"22","author":"J Hendrikx","year":"2017","unstructured":"Hendrikx J, et al. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22(10):1212\u201321.","journal-title":"Oncologist"},{"issue":"9","key":"1170_CR14","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0091270009337512","volume":"49","author":"DD Wang","year":"2009","unstructured":"Wang DD, et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49(9):1012\u201324.","journal-title":"J Clin Pharmacol"},{"key":"1170_CR15","unstructured":"Elranatamab (ELREXFIO) Mutli-Discipline Review. 2023. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761345Orig1s000MultidisciplineR.pdf. Accessed 19 Mar 2025."},{"issue":"9","key":"1170_CR16","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"issue":"8","key":"1170_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1170_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1170_CR19","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29(10):2570\u20136.","journal-title":"Nat Med"},{"key":"1170_CR20","unstructured":"Tebentafusp-tebn (Kimmtrak) Mutli-Discipline Review. 2021. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761228Orig1s000MultidisciplineR.pdf. Accessed 19 Mar 2025."},{"key":"1170_CR21","unstructured":"Mosunetuzumab (Lunsumio) Mutli-Discipline Review. 2022. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761263Orig1s000MultidisciplineR.pdf. Accessed 19 Mar 2025."},{"key":"1170_CR22","unstructured":"Epcoritamab (Epkinly) Mutli-Discipline Review. 2023. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761324Orig1s000MultidisciplineR.pdf. Accessed 19 Mar 2025."},{"key":"1170_CR23","unstructured":"Glofitamab-gxbm (Columvi) Mutli-Discipline Review. 2023. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761309Orig1s000MultidisciplineR.pdf. Accessed 19 Mar 2025."},{"key":"1170_CR24","unstructured":"Tarlatamab (IMDELLTRA) Mutli-Discipline Review. 2023. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761344Orig1s000MultidisciplineR.pdf. Accessed 19 Mar 2025."},{"key":"1170_CR25","unstructured":"Talquetamab-tgvs (TALVEY) Mutli-Discipline Review. 2023. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761342Orig1s000MultidisciplineR.pdf. Accessed 19 Mar 2025."},{"key":"1170_CR26","unstructured":"Teclistamab (TECVAYLI) Mutli-Discipline Review. 2021. FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761291Orig1s000MultidisciplineR.pdf. Accessed 19 Mar 2025."},{"issue":"1","key":"1170_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13717","volume":"17","author":"Y Guo","year":"2024","unstructured":"Guo Y, et al. Teclistamab: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1): e13717.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1170_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao X, et al. Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1. Target Oncol. 2023;18(5):667\u201384.","journal-title":"Target Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01170-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:57:19Z","timestamp":1772445439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01170-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01170-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"4 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.E., P.S., J.H., O.A., D.W., and H.L. report employment and stock ownership at Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Upon request and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified patient data. See\n                      \n                      for more information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"The study was conducted in accordance with the ethics principles of the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines, and the International Council for Harmonization Good Clinical Practice Guidelines. All relevant documents, including amendments, were reviewed and approved by the institutional review board and\/or ethics committee of each participating center.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the trial conception\/design, or the acquisition, analysis, or interpretation of data. All authors contributed to the drafting of the manuscript and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}